PURPOSE: The aim of this Phase II study was to assess the efficacy and safety of vandetanib in combination with docetaxel in patients with pretreated advanced breast cancer. METHODS: The primary study objective was to compare the number of progression events in patients receiving once-daily oral vandetanib (100 mg) in combination with docetaxel (100 mg/m(2) iv every 21 days) versus placebo plus docetaxel. Sixty-four patients were randomized to receive study treatment (n = 35, vandetanib; n = 29, placebo). RESULTS: A slightly greater number of patients had experienced a progression event by the data cut-off in the vandetanib group (24 [69%]) compared with the placebo group (18 [62%]); HR = 1.19, two-sided 80% CI: 0.79-1.81; two-sided P = 0.59), suggesting that the addition of vandetanib to docetaxel did not affect the risk of disease progression compared with placebo plus docetaxel. The safety and tolerability profile of the combination therapy reflected those of both drugs as monotherapy agents. CONCLUSIONS: In patients with advanced breast cancer, vandetanib plus docetaxel was generally well tolerated. Clinical benefit was not different to that observed with placebo plus docetaxel. However, due to the small patient number it was not possible to yield robust results, further research is required to identify predictive factors for patient selection.
PURPOSE: The aim of this Phase II study was to assess the efficacy and safety of vandetanib in combination with docetaxel in patients with pretreated advanced breast cancer. METHODS: The primary study objective was to compare the number of progression events in patients receiving once-daily oral vandetanib (100 mg) in combination with docetaxel (100 mg/m(2) iv every 21 days) versus placebo plus docetaxel. Sixty-four patients were randomized to receive study treatment (n = 35, vandetanib; n = 29, placebo). RESULTS: A slightly greater number of patients had experienced a progression event by the data cut-off in the vandetanib group (24 [69%]) compared with the placebo group (18 [62%]); HR = 1.19, two-sided 80% CI: 0.79-1.81; two-sided P = 0.59), suggesting that the addition of vandetanib to docetaxel did not affect the risk of disease progression compared with placebo plus docetaxel. The safety and tolerability profile of the combination therapy reflected those of both drugs as monotherapy agents. CONCLUSIONS: In patients with advanced breast cancer, vandetanib plus docetaxel was generally well tolerated. Clinical benefit was not different to that observed with placebo plus docetaxel. However, due to the small patient number it was not possible to yield robust results, further research is required to identify predictive factors for patient selection.
Authors: F Ciardiello; R Caputo; R Bianco; V Damiano; G Fontanini; S Cuccato; S De Placido; A R Bianco; G Tortora Journal: Clin Cancer Res Date: 2001-05 Impact factor: 12.531
Authors: Lawrence V Rubinstein; Edward L Korn; Boris Freidlin; Sally Hunsberger; S Percy Ivy; Malcolm A Smith Journal: J Clin Oncol Date: 2005-10-01 Impact factor: 44.544
Authors: Andreas Polychronis; H Dudley Sinnett; Dimitri Hadjiminas; Hemant Singhal; Janine L Mansi; Dharsha Shivapatham; Sami Shousha; Jie Jiang; David Peston; Nigel Barrett; David Vigushin; Ken Morrison; Emma Beresford; Simak Ali; Martin J Slade; R Charles Coombes Journal: Lancet Oncol Date: 2005-06 Impact factor: 41.316
Authors: G Gasparini; M Toi; M Gion; P Verderio; R Dittadi; M Hanatani; I Matsubara; O Vinante; E Bonoldi; P Boracchi; C Gatti; H Suzuki; T Tominaga Journal: J Natl Cancer Inst Date: 1997-01-15 Impact factor: 13.506
Authors: H J Burstein; A M Storniolo; S Franco; J Forster; S Stein; S Rubin; V M Salazar; K L Blackwell Journal: Ann Oncol Date: 2008-02-17 Impact factor: 32.976
Authors: J G Klijn; M P Look; H Portengen; J Alexieva-Figusch; W L van Putten; J A Foekens Journal: Breast Cancer Res Treat Date: 1994-01 Impact factor: 4.872
Authors: Melody A Cobleigh; Virginia K Langmuir; George W Sledge; Kathy D Miller; Latrice Haney; William F Novotny; James D Reimann; Amy Vassel Journal: Semin Oncol Date: 2003-10 Impact factor: 4.929
Authors: F Ciardiello; T Troiani; F Caputo; M De Laurentiis; G Tortora; G Palmieri; F De Vita; M R Diadema; M Orditura; G Colantuoni; C Gridelli; G Catalano; S De Placido; A R Bianco Journal: Br J Cancer Date: 2006-06-05 Impact factor: 7.640
Authors: Philip M Spanheimer; Allison W Lorenzen; James P De Andrade; Mikhail V Kulak; Jennifer C Carr; George W Woodfield; Sonia L Sugg; Ronald J Weigel Journal: Ann Surg Oncol Date: 2015-05-14 Impact factor: 5.344
Authors: Erica L Mayer; Steven J Isakoff; Giannoula Klement; Sean R Downing; Wendy Y Chen; Keri Hannagan; Rebecca Gelman; Eric P Winer; Harold J Burstein Journal: Breast Cancer Res Treat Date: 2012-09-23 Impact factor: 4.872